Fig. 2: Public transcriptomics datasets reveal subset of MASLD patients with hepatic ferroptosis susceptibility signature. | Cell Death & Differentiation

Fig. 2: Public transcriptomics datasets reveal subset of MASLD patients with hepatic ferroptosis susceptibility signature.

From: Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease

Fig. 2

Hepatic expression of ferroptosis-related genes studied in three cohorts of MASLD patients and controls. Genes were grouped in gene sets for which each patient received a gene set variation analysis (GSVA) score. Higher GSVA scores for “ferroptosis defenses” and “GSH” indicate upregulated ferroptosis defenses and increased glutathione (GSH) synthesis, respectively. Higher “PUFA” and “Iron” scores indicate drive toward more PUFA in phospholipids for ferroptosis. A GSVA scores for patients in three clusters determined by Gaussian Mixture modeling in GSE130970 (n = 78). Table displaying distribution of histologic groups across different clusters. B, C Patients from GSE135251 (n = 206) and GSE126848 (n = 57) received GSVA scores for four gene sets and cluster membership. Red clusters represent ferroptosis-sensitizing PUFA incorporation together with lowered ferroptosis defenses; green clusters exhibit highly expressed ferroptosis defenses. Violin plots show median and quartiles. *p < 0.05; **p < 0.01; ***p < 0.001; Kruskal–Wallis with Dunn’s test.

Back to article page